Millie
your market intelligence analyst
Search Results
454 results
Your search is now limited to «Prostate Cancer» expert search.
In this retrospective cohort study, 58 patients underwent cytoreductive radical prostatectomy and ADT.
More from International Journal of COPD:
PR Newswire 09/22/2020 17:59
The bill would also direct the VHA to develop a national clinical pathway for prostate cancer and design a Prostate Cancer Registry and Research Program.
More from PR Newswire:
Healio News 09/22/2020 10:43
The addition of ipatasertib to abiraterone enhanced antitumor activity and improved radiographic PFS as first-line therapy for metastatic castration-resistant prostate cancer, according to data presented at ESMO Virtual Congress 2020. Researchers observed these benefits in the randomized phase 3 IPATential150 study among men whose tumors had PTEN loss. “Metastatic castration-resistant prostate cancer [mCRPC] is a heterogeneous disease, with approximately half of these tumors having lost the AKT phosphatase PTEN, hyperactivating oncogenic PI3K/AKT signaling,” Johann S. de Bono, MD,
More from Healio News:
ClinicalTrials.gov 09/22/2020 07:53
Condition : Prostate Cancer Interventions : Drug: Testosterone Cypionate; Drug: Darolutamide Sponsors : Latin American Cooperative Oncology Group; Bayer Not yet recruiting.
More from ClinicalTrials.gov:
Business Wire 09/21/2020 15:35
Data from the Phase III ARAMIS trial of men receiving NUBEQA plus ADT were analyzed ad hoc to determine tolerability and association of prostate-specific antigen (PSA) decline in response to treatment with NUBEQA plus ADT and metastasis-free survival (MFS.
More from Business Wire:
Oncology Central 09/21/2020 09:56
A major Phase III trial has demonstrated that a precision drug, termed ipatasertib, in combination with abiraterone can treat an aggressive group of prostate cancers that lack a functioning PTEN gene.
More from Oncology Central:
AstraZeneca - Press Releases 09/21/2020 02:05
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations.
News-Medical.net 09/21/2020 01:18
In addition, clinical guidelines have been elaborated by ESMO, the National Comprehensive Cancer Network (NCCN), and American Urological Association (AUA), among others, that now recommend genomic sequencing of patients with advanced prostate cancer to identify which patients would most likely benefit from this novel and personalized treatment approach.
More from News-Medical.net:
FeedNavigator (EU) 09/19/2020 02:22
To investigate the influence factors of infection complications of transrectal ultrasound-guided transperineal prostate biopsy. A total of 2192 patients wh.
More from FeedNavigator (EU):
GlobeNewswire 09/18/2020 07:30
The oral presentation is entitled “Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent.
More from GlobeNewswire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications